ARCHIVES

Lasagna Committee Report Advocates Faster Drug approval, Insurance Coverage For Investigational Drugs, Ancillary Costs

This article is from The Cancer Letter archive.

Vol. 16 No. 34 | September 7, 1990

Download PDF Visit The Full Archive

Related Articles

Elevated Baseline Glucose Levels Associated With Higher Cancer Risk

November 25, 2011

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

May 11, 2007

ODAC Rejects Temodal for Melanoma After Discussion Of Approval Standards

April 2, 1999

In Brief: INTRA-NCI Scramble For Funds involves “Tricks, Machinations, Day To Day Battle”

July 16, 1976

Federal Budget Cuts Implemented March 1; HHS Agencies Grapple with Consequences

March 8, 2013

Clinical Education Guidelines Proposed

April 4, 1975